Tirzepatide

Tirzepatide is a dual GIP and GLP-1 receptor agonist that affects appetite, satiety, gastric emptying, and glucose-dependent insulin signaling. It has one of the strongest human evidence bases among the treatments on Bowery Clinic’s metabolic and body-composition menu. Large randomized trials have shown substantial and sustained weight reduction in adults with obesity or overweight when injectable Tirzepatide was combined with lifestyle intervention SURMOUNT-1 trial. Tirzepatide is a metabolic and appetite-regulation treatment that can support fat loss, waist reduction, and improved cardiometabolic markers.

Tirzepatide activates both GIP and GLP-1 receptors. That combination reduces appetite and food intake, slows gastric emptying—especially earlier in treatment—and improves glucose-dependent insulin signaling. In SURMOUNT-1, participants receiving injectable Tirzepatide achieved large average reductions in body weight over 72 weeks, with improvements in multiple cardiometabolic measures trial. Body-composition research also shows that the majority of the weight lost with Tirzepatide is fat mass, although some lean mass is lost as well. In a DXA substudy, roughly three-quarters of the weight lost was fat mass and one-quarter lean mass body-composition study.

Tirzepatide has extensive human safety data, but it should still be prescribed after medical screening. The most common side effects are gastrointestinal—such as nausea, diarrhea, constipation, vomiting, or reduced appetite—and are often most noticeable during dose escalation. In SURMOUNT-1, gastrointestinal adverse events were the most common treatment-related issues clinical trial. Your clinician will review personal and family history, current medications, gastrointestinal disease, gallbladder or pancreatic history, hydration, and other relevant contraindications before treatment. A lower or slower titration may be appropriate for patients who are sensitive to appetite suppression or who want body recomposition without aggressive weight loss.

Tirzepatide can begin affecting appetite and fullness within the first week. Meaningful weight change is usually assessed over the first 4–12 weeks, while larger body-composition changes continue to develop over 3–6 months and beyond. Because the dose is commonly increased gradually, early weeks should be viewed as the beginning of the treatment response rather than the final result.

Bowery Clinic peptides are higher-strength and clinically dosed compared to most research facilities that use much lower concentrations. They are compounded by licensed 503A pharmacies with physician oversight and sterile quality standards, prioritizing real therapeutic outcomes over cheaper, unregulated research-grade products.

Yes. All pharmacies in our network are fully licensed in the states where they operate and comply with all state board of pharmacy regulations. Unlike many peptide clinics, we partner exclusively with FDA-registered U.S. pharmacies that undergo rigorous evaluation and compliance checks.

Every patient receives treatment plans developed and monitored by licensed providers. This includes safe titration of dosages and ongoing medical oversight tailored to individual needs.

Injections deliver the medication directly into your system. This makes the absorption more consistent and effective. Troches are small dissolvable lozenges that sit in your mouth until they melt, slowly releasing medication through the lining of your cheek or under your tongue.